Tag: DCB
Cardiovascular Systems and Chansu Vascular Technologies partner to develop new everolimus DCBs
Cardiovascular Systems (CSI) has partnered with Chansu Vascular Technologies (CVT) to develop no...
Paclitaxel coated balloons have lower risk of mortality in coronary arteries at three years than control treatments
Paclitaxel drug coated balloons (DCB) for percutaneous treatment of coronary artery disease (CAD...
Customising therapy in femoropopliteal revascularisation
Gary Ansel (Columbus, USA) tells Vascular News at VEITHSymposium 2018 about how drug-based ther...
Meta-analysis finds a higher risk of death in the long term when paclitaxel-coated devices are used in the leg
New data, just published in the Journal of the American Heart Association (JAHA), suggest that t...
